New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
09:31 EDTNSRGY, VRXValeant completes filler, toxin asset sale to Galderma
Valeant Pharmaceuticals (VRX) announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4B in cash, pursuant to the previously announced agreement with Nestle (NSRGY) which recently completed its acquisition of Galderma.
News For VRX;NSRGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
May 20, 2015
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 15, 2015
17:15 EDTVRXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTVRXSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTVRXPershing Square gives quarterly update on stakes
Subscribe for More Information
10:55 EDTVRXJANA Partners gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use